Exosomes and the Future of Immunotherapy in Pancreatic Cancer

Exosomes and the Future of Immunotherapy in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, associated with a late diagnosis and a five-year survival rate of 8%. Currently available treatments fall short in improving the survival and quality of life of PDAC patients. The only possible curative option is still the surgical re...

Full description

Bibliographic Details
Main Authors: Ines A. Batista, Sonia A. Melo
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:International Journal of Molecular Sciences
Subjects:
pancreatic cancer
exosomes
immunotherapy
Online Access:https://www.mdpi.com/1422-0067/20/3/567

Similar Items

Similar Items